Introduction
Prion diseases or transmissible spongiform encephalopathies are neurodegenerative disorders that can be sporadic, inherited, or acquired by infection (2, 3) . The underlying pathogenetic event in all prion diseases is a conformational modification of the normal or cellular prion protein (PrP C ) from a soluble form with a predominant α-helical conformation to the pathogenic form that is aggregated, rich in β-sheets, and partially resistant to proteinase-K (PK) digestion (PrP Sc ) (2, 4) . According to the 'protein only' hypothesis, PrP Sc interacts directly with the host-encoded PrP C , which is then converted to PrP Sc . PrP Sc accumulates in the nervous tissue, and when it reaches a critical threshold, causes disease (2) .
Several lines of evidence indicate that the PrP C to PrP Sc conversion is mediated by chaperone(s) (5) . Molecular chaperones Hsp104 and GroEL have been shown to promote the conversion reaction of mammalian PrP C in a cell-free system and the conversion of prion-like proteins in intact yeast cells (6) (7) (8) . Several chemical chaperones have been shown to act as conversion inhibitors (6) . Data from transgenic animal models argue for the requirement of an accessory protein for the refolding of PrP C to PrP Sc . This protein, temporarily named protein X, remains to be identified (2) , and may very well be a cellular chaperone.
In the inherited forms of human prion diseases, which include Gerstmann-Sträussler-Scheinker (GSS) disease, Creutzfeldt-Jakob disease (CJD) and fatal familial insomnia, mutations in the prion protein gene (PRNP) are believed to destabilize the mutant PrP, which then easily converts to PrP Sc (2, 4) . Our series of studies using human neuroblastoma cell models of inherited prion diseases are indeed consistent with this hypothesis (1, 9) . Although these models do not lead to rapidly degraded through the proteasomal system (9) . If proteasomal function is impaired, the mutant PrP accumulates in an insoluble and weakly PK-resistant form in the endoplasmic reticulum (ER) and post-ER compartments (1, 9) .
These findings argue that chaperones play a double role in inherited prion diseases. They are likely to be involved not only in the conversion of PrP to PrP Sc as in other forms of prion diseases (6) , but may also play a role in the destabilizing effect that the PRNP mutations have on the mutant PrP. Interaction of mutant PrP with chaperones might promote its degradation and delay the conversion to PrP Sc , helping to explain the conundrum of why inherited prion diseases often manifest clinically only late in life although the mutation is present from conception.
To begin to unravel the role of chaperones in prion diseases, PRNP-transfected neuroblastoma cells were used to examine the role of ER-localized molecular chaperones in the processing of normal and mutant PrP. The mutation at PRNP codon 217 resulting in the substitution of glutamine to arginine (Q217R) in the mutant PrP (PrP 217 ) is associated with a GSS disease phenotype that presents in the seventh decade and is characterized by a slowly progressive dementia associated with cerebellar and extrapyramidal signs (10) . The histopathological hallmark of the Q217R GSS variant is the presence of PrP 217 containing amyloid deposits and neurofibrillary degeneration in the brain tissue (10) . In a previous study carried out on a transfected neuroblastoma cell model of GSS Q217R, we showed that a significant proportion of 
Metabolic labeling and immunoprecipitation:
In a typical experiment, 9x10 6 cells were used for each cell line. Immunoprecipitation was performed essentially as described (1, 9) , with the following modifications. As we have reported in a previous study, mature PrP C migrates as three distinct bands, which correspond to the PrP C with two, one, and no glycans respectively. In contrast, PrP 217 shows an additional band of 32kDa (PrP32), which migrates at ~30kDa (rather than at 27kDa as PrP following treatment with detergent that permeabilizes all cellular membranes, a small amount of PrP C is observed in the Golgi region, while PrP 217 is present in much larger quantity, and for the most part co-distributes with the ER (panels 5 and 6). Therefore, following inhibition of proteasomal degradation, PrP32 does not form an aggresome-like structure in the cytosol, as has been reported for other secretory proteins degraded by the proteasome (12, 13).
Discussion
BiP has been shown to promote proper folding of newly synthesized polypeptides by keeping the precursors in a soluble state (12, (14) (15) (16) (17) . It interacts transiently with proteins, which presumably are properly folded. In contrast, it binds misfolded or unassembled proteins in relatively stable complexes and may mediate their retrograde translocation for proteasomal degradation (18) (19) (20) (21) (22) (23) (24) (25) (26) .
Our data provide the first evidence that BiP plays these roles in the processing of PrP. BiP briefly interacts in the ER with PrP C ( Figure 3A Regardless of the mechanism, it is remarkable that two major types of Q217R mutant PrP, PrP 217 and PrP32, interact differently with BiP, and following this interaction are processed through different routes. PrP 217 aggregates in a post-Golgi compartment, most likely the endosomallysosomal system, and eventually is degraded since it does not accumulate. In contrast, PrP32 remains largely soluble, and is degraded by the proteasome. However, inhibition of proteasomal function, which has no effect on PrP 217 , results in increased amounts of PrP32 in the ER and the cytosol. Presumably, the impairment of the endosomal-lysosomal degradation leads to the accumulation of PrP 217 . Thus, each of the two forms of Q217R mutant PrP has the potential to perturb the cellular metabolism, but by distinct mechanisms.
We have previously shown that another mutant PrP caused by the presence of a stop codon at PRNP position 145 (PrP 145 ) is also degraded by the proteasomal pathway (9) . PrP 145 is Cterminus truncated, lacks the anchor and is associated with a GSS phenotype. Therefore, proteasomal degradation is shared by mutant PrP variants lacking the GPI anchor. However, unlike PrP32, PrP 145 is not bound to BiP, perhaps because part or the whole C-terminal region is needed for this binding.
In addition to PrP, several other secretory and membrane proteins implicated in causing disease are degraded by the proteasomal pathway when they are mutated, and aggregate in intracellular compartments following the inhibition of proteasomal function (12, 25, 26, (33) (34) (35) (36) (37) . The proteins implicated in neurodegeneration include huntingtin that forms intranuclear aggregates in Huntington's disease, ataxins 1 and 3 associated with forms of spinocerebellar ataxia (38-41),
DQG .-synuclein, the major component of the cytoplasmic Lewy bodies in Parkinson's disease (42) . The central theme in these disorders, as in prion diseases, is the conversion of a normally VROXEOH DQG IXQFWLRQDO SURWHLQ LQWR D -sheet rich structure that is insoluble, aggregates, and forms intracellular deposits. Contrary to previous assumptions, it appears now that intranuclear aggregates of huntingtin may have a protective role rather than causing neuronal damage (40, 41) . Mutant huntingtin has been shown to be toxic in the absence of aggregates (41) and it is argued that by capturing the toxic protein the aggregate may protect the cell from this toxicity.
Thus, the neurotoxic cascade might start before the formation of aggregates, possibly by soluble intermediates that escape degradation (43) . Our results on PrP32 are consistent with this scenario. Although BiP prevents the aggregation and facilitates degradation of PrP32, it may in fact render PrP32 more pathogenic by maintaining it in a partially unfolded state in the ER, especially if BiP promotes the re-folding of PrP32 into an alternative, more pathogenic form, instead of its aggregation when proteasomal function is compromised.
In conclusion, the present finding that the two mutant PrP variants generated by the Q217R PRNP mutation are processed through entirely different metabolic pathways underscores the complexity and diversity of the pathogenic perturbation that may be caused by a simple point mutation. Only a detailed study of the metabolism of the mutant protein can bring to light this complexity, which must be understood before the optimal therapeutic intervention can be established. 
